Servier secures EC approval of LONSURF for treating metastatic gastric cancer
Phase III trial TAGS is designed to evaluate LONSURF in combination with best supportive care (BSC), with placebo…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Sep 19
Phase III trial TAGS is designed to evaluate LONSURF in combination with best supportive care (BSC), with placebo…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Sep 19
Theragnostics’ technology platform enables the development of molecular radiotherapy based on a PARPi for imaging and treating cancer
04 Sep 19
US-based biopharmaceutical company Vertex has signed a definitive agreement to acquire Semma Therapeutics, a USK-based biotechnology company, for…
30 Aug 19
The chemotherapy is advised for TNBC patients whose tumours have PD-L1 expression and have not received prior chemotherapy…
28 Aug 19
IDT employs a unique solid-support manufacturing platform, to produce long oligos more accurately, rapidly, and reliably
27 Aug 19
The closing of the transaction is subject to the signing of a consent decree by Bristol-Myers Squibb and…
26 Aug 19
BREEZE-AD7 is an investigational study designed to evaluate the efficacy and safety of baricitinib, and marks the third…
26 Aug 19
Gilead Sciences is a research-based biopharmaceutical company engaged in discovery, development and commercialisation of medication
23 Aug 19
ViiV has co-developed the injectable regimen in collaboration with Janssen Sciences and has submitted to regulatory authorities in…
22 Aug 19
Pfizer intends to strengthen its production and supply capabilities of critical, potentially life-changing gene therapy medicines by expanding…